La cadena de opciones muestra datos clave de las opciones de acciones de NewGenIvf Group a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para NewGenIvf Group..

NewGenIvf Group (NASDAQ:NIVF) Bolsa, Cadena de Opciones

NewGenIvf Group

NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group Ltd

WIIM

RIME

Algorhythm Holdings shares are trading higher after its subsidiary SemiCab won a new pilot program with the 6th largest global consumer package goods company.

Macro Economic Events

Economics

Federal Reserve

Fed Policymakers See 4.3% Unemployment Rate At End Of 2025 Versus 4.4% In September Projections; End-2025 PCE Inflation At 2.5% Versus 2.1% In September; Core Seen At 2.5% Versus 2.2%; 2.1% GDP Growth In 2025 Versus 2.0% In September, See Longer-run Growth At 1.8%, Unchanged From September

Fed Projections Imply 50 Basis Points Of Rate Cuts In 2025, Another 50 Bps In 2026; Fed Policy Rate Reaching 3.1% In 2027; Show Longer-run Policy Rate At 3.0% Vs 2.9% In September Projections; One Of 19 Officials See No Cuts In 2025, 3 See One Cut, 10 See 2 Cuts, 3 See 3 Cuts, One Sees 4 Cuts, One Sees 5 Cuts; Stronger Growth And Stronger Inflation In 2025

Fed Officials' Median View Of Fed Funds Rate At End-2024 4.4% (Prev 4.4%); Fed Officials' Median View Of Fed Funds Rate At End-2025 3.9% (Prev 3.4%); Fed Officials' Median View Of Fed Funds Rate At End-2026 3.4% (Prev +2.9%); Fed Officials' Median View Of Fed Funds Rate At End-2027 3.1% (Prev +2.9%); Fed Officials' Median View Of Fed Funds Rate In Longer Run 3.0% (Prev 2.9%)

Macro Notification

General

Fed Says In Considering 'extent And Timing' Of Additional Rate Adjustments Fed Will Assess Incoming Data, Evolving Outlook, Balance Of Risks; Lowers Reverse Repo Rate By 30 Basis Points To 4.25% Versus 25 Bps Cut To Fed Funds Rate; Fed Vote In Favor Of Rate Cut Was 11-1; Cleveland Fed President Hammack Dissented, Preferring To Leave Policy Rate Unchanged

Small Cap

Federal Reserve Cuts Key Overnight Interest Rate 25 Basis Points To 4.25-4.50% Range; New Projections Show 50 Bps Of Cuts In 2025; Fed Policy Statement Little Changed From November Meeting Statement; Descriptions Of Economy Growing At Solid Pace Are Identical

Analysts' ratings for Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) over the last quarter vary from bullish to bearish, as provided by 23 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">13</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $92.87, with a high estimate of $135.00 and a low estimate of $70.00. This current average reflects an increase of 26.05% from the previous average price target of $73.68. 
<img src="https://www.benzinga.com/files/images/story/2024/1734548458_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Twilio's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$110.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian White</td>
<td>Monness, Crespi, Hardt</td>
<td>Announces</td>
<td>Buy</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Michael Latimore</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$86.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$85.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$85.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$77.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Twilio. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Twilio compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Twilio's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Twilio's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TWLO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Twilio analyst ratings.</a>
<h2>About Twilio</h2>
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
<h3>Financial Insights: Twilio</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Twilio showcased positive performance, achieving a revenue growth rate of 9.67% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.86%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.11%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Twilio's ROA excels beyond industry benchmarks, reaching -0.09%. This signifies efficient management of assets and strong financial health.
Debt Management: Twilio's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

TWLO

Demystifying Twilio: Insights From 23 Analyst Reviews

Ratings for PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for PTC, presenting an average target of $217.29, a high estimate of $230.00, and a low estimate of $195.00. Witnessing a positive shift, the current average has risen by 7.04% from the previous average price target of $203.00.
<img src="https://www.benzinga.com/files/images/story/2024/1734548446_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive PTC. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$228.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$202.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$226.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to PTC. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PTC compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for PTC's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of PTC's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PTC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PTC analyst ratings.</a>
<h2>About PTC</h2>
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America (45%) and Europe (40%).
<h3>PTC's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, PTC showcased positive performance, achieving a revenue growth rate of 14.62% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: PTC's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.19% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): PTC's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 4.06%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): PTC's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.02%, the company may face hurdles in achieving optimal financial performance.
Debt Management: PTC's debt-to-equity ratio surpasses industry norms, standing at 0.6. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying PTC: Insights From 7 Analyst Reviews

Throughout the last three months, 11 analysts have evaluated TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.0, a high estimate of $42.00, and a low estimate of $31.00. Observing a 5.11% increase, the current average has risen from the previous average price target of $34.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1734548435_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of TechnipFMC by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Ati Modak</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Victoria McCulloch</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Abhishek Kumar</td>
<td>HSBC</td>
<td>Announces</td>
<td>Buy</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Chase Mulvehill</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Phillip Jungwirth</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to TechnipFMC. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of TechnipFMC compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for TechnipFMC's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of TechnipFMC's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FTI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TechnipFMC analyst ratings.</a>
<h2>Discovering TechnipFMC: A Closer Look</h2>
TechnipFMC is the largest pure-play offshore oilfield service provider, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea engineering and construction services. The company also provides various surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of predecessor companies Technip and FMC Technologies.
<h3>Financial Insights: TechnipFMC</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining TechnipFMC's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.17% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: TechnipFMC's net margin is impressive, surpassing industry averages. With a net margin of 11.69%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): TechnipFMC's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.81% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): TechnipFMC's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.9% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: TechnipFMC's debt-to-equity ratio is below the industry average at 0.6, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 11 Analyst Projections For TechnipFMC

In the preceding three months, 4 analysts have released ratings for Huntsman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $22.75, a high estimate of $25.00, and a low estimate of $19.00. A 2.15% drop is evident in the current average compared to the previous average price target of $23.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1734548427_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Huntsman's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Huntsman. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Huntsman compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Huntsman's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Huntsman's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Huntsman analyst ratings.</a>
<h2>Unveiling the Story Behind Huntsman</h2>
Huntsman Corp is a us-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. It derives most of its revenue from the Polyurethanes segment which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States &amp; Canada, Europe, Asia-Pacific, and the Rest of the world.
<h3>Key Indicators: Huntsman's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Huntsman showcased positive performance, achieving a revenue growth rate of 2.26% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Huntsman's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Huntsman's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.06%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Huntsman's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.45%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.73.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Huntsman Stock

<a href="https://www.federalreserve.gov/newsevents/pressreleases/monetary20241218a.htm">https://www.federalreserve.gov/newsevents/pressreleases/monetary20241218a.htm</a>
Recent indicators suggest that economic activity has continued to expand at a solid pace. Since earlier in the year, labor market conditions have generally eased, and the unemployment rate has moved up but remains low. Inflation has made progress toward the Committee's 2 percent objective but remains somewhat elevated.
The Committee seeks to achieve maximum employment and inflation at the rate of 2 percent over the longer run. The Committee judges that the risks to achieving its employment and inflation goals are roughly in balance. The economic outlook is uncertain, and the Committee is attentive to the risks to both sides of its dual mandate.
In support of its goals, the Committee decided to lower the target range for the federal funds rate by 1/4 percentage point to 4-1/4 to 4-1/2 percent. In considering the extent and timing of additional adjustments to the target range for the federal funds rate, the Committee will carefully assess incoming data, the evolving outlook, and the balance of risks. The Committee will continue reducing its holdings of Treasury securities and agency debt and agency mortgage‑backed securities. The Committee is strongly committed to supporting maximum employment and returning inflation to its 2 percent objective.
In assessing the appropriate stance of monetary policy, the Committee will continue to monitor the implications of incoming information for the economic outlook. The Committee would be prepared to adjust the stance of monetary policy as appropriate if risks emerge that could impede the attainment of the Committee's goals. The Committee's assessments will take into account a wide range of information, including readings on labor market conditions, inflation pressures and inflation expectations, and financial and international developments.
Voting for the monetary policy action were Jerome H. Powell, Chair; John C. Williams, Vice Chair; Thomas I. Barkin; Michael S. Barr; Raphael W. Bostic; Michelle W. Bowman; Lisa D. Cook; Mary C. Daly; Philip N. Jefferson; Adriana D. Kugler; and Christopher J. Waller. Voting against the action was Beth M. Hammack, who preferred to maintain the target range for the federal funds rate at 4-1/2 to 4-3/4 percent.

Federal Reserve Issues FOMC Statement December 18, 2024

11 analysts have expressed a variety of opinions on Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $112.09, a high estimate of $125.00, and a low estimate of $104.00. This upward trend is apparent, with the current average reflecting a 1.73% increase from the previous average price target of $110.18.
<img src="https://www.benzinga.com/files/images/story/2024/1734548418_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Eastman Chemical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$117.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$119.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$107.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eastman Chemical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Eastman Chemical compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Eastman Chemical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Eastman Chemical's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EMN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eastman Chemical analyst ratings.</a>
<h2>Get to Know Eastman Chemical Better</h2>
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
<h3>Understanding the Numbers: Eastman Chemical's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Eastman Chemical showcased positive performance, achieving a revenue growth rate of 8.69% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Eastman Chemical's net margin is impressive, surpassing industry averages. With a net margin of 7.31%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Eastman Chemical's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.2% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Eastman Chemical's debt-to-equity ratio is below the industry average. With a ratio of 0.89, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Eastman Chemical Stands With Analysts

LAES

SealSq shares are trading lower after the company announced a registered offering of $13.16 million shares priced at $1.90 per unit for approximate proceeds of $25 million.

When <a href="https://www.benzinga.com/money/how-to-build-a-real-estate-portfolio">building a real estate portfolio</a>, protecting your assets is just as important as growing them. Dave Ramsey, the personal finance guru, knows this all too well. During an <a href="https://www.youtube.com/watch?v=vkPZCGgoqmY">episode</a> of The Ramsey Show, he shared a practical tip that every <a href="https://www.benzinga.com/money/how-to-become-a-real-estate-investor">aspiring real estate investor</a> should hear: <a href="https://www.benzinga.com/money/how-to-buy-rental-property-with-an-llc">set up a new LLC</a> once your real estate holdings hit a certain number.
Here's why Dave swears by this approach – and what it means for investors.
Don't Miss:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/go/arrived-private-credit-yf">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a></li>
</ul>
<h2 class="wp-block-heading">Protecting Your Assets from Unexpected Twists</h2>
Ramsey wants you to imagine this: you own a rental property and one day a tenant gets drunk, falls off the porch and decides to sue you. Scary, right? This nightmare scenario is exactly what an LLC (Limited Liability Company) is designed to handle, among other things. According to Dave, when an LLC owns a rental property, the tenant can only sue the LLC, not you personally.
"If they were to win," Dave explained, the most they'll get is what that LLC owns. That means your home, bank accounts and other investments remain safe. For Dave, this is nonnegotiable.
See Also: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-y2">The deadline to invest and receive your shares this year is 12/20. Join 30,000+ shareholders and invest at $0.26/share today.</a>
<h2 class="wp-block-heading">When to Start a New LLC</h2>
When Dave Ramsey was actively buying residential properties, he would group them into LLCs with a total value of up to $5 million. Once an LLC reached that threshold, he would form a new one to limit risk.
If one LLC&#8217;s assets are involved in a lawsuit, only those properties are at stake. By spreading his properties across multiple LLCs, Dave ensures that no single lawsuit can wipe out his entire portfolio. For larger properties, like a $15 million office building he owns, he creates stand-alone LLCs.
This strategy isn't just for multimillionaires. Even if you're starting small, grouping your properties into an LLC can give you peace of mind – and a safety net.
Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks-y2">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">Flipping vs. Renting: Know What You're Signing Up For</h2>
Dave also touched on the age-old question for real estate investors: Should you <a href="https://www.benzinga.com/money/what-is-flipping-houses">flip properties</a> or hold them as rentals? His take is that flipping can be lucrative, but it's also time-consuming. "Flips are a pain in the butt," Dave admitted. You'll spend hours managing contractors, picking paint colors and pulling permits. It's a job, not a passive investment.
On the other hand, rentals provide steady income, but they're not hassle-free. Dave pointed out that cheaper properties offer higher returns but often have difficult tenants. High-end properties attract more stable tenants but yield lower returns. Either way, <a href="https://www.benzinga.com/money/managing-rental-properties">managing rentals requires active involvement</a>.
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=stockmarket-yahoo"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
<h2 class="wp-block-heading">The Myth of Passive Income</h2>
If you're picturing yourself collecting easy checks every month, think again. Dave didn't mince words: "People who say passive income on real estate are morons. There's <a href="https://www.benzinga.com/real-estate/24/05/38648012/dave-ramsey-says-theres-nothing-passive-about-being-a-landlord-how-to-invest-in-real-estate-for-trul">nothing passive</a> about owning real estate."
Owning real estate is a hands-on business, whether managing tenants, fixing leaky pipes or handling legal issues. That's why Dave emphasizes understanding the challenges before jumping in.
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>The<a href="https://www.benzinga.com/go/equitymultiple-yf"> Ascent Income Fund</a> from EquityMultiple targets stable income from senior commercial real estate debt positions and has a historical distribution yield of 12.1% backed by real assets.<a href="https://www.benzinga.com/go/equitymultiple-yf"> Earn a 1% return boost on your first EquityMultiple investment when you sign up here (accredited investors only)</a>.</li>
</ul>

If They Win …' – Here's The Savvy Reason Dave Ramsey Launches A New Real Estate LLC After Hitting $5 Million

In the last three months, 7 analysts have published ratings on 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $2.84, a high estimate of $4.00, and a low estimate of $2.00. A 8.68% drop is evident in the current average compared to the previous average price target of $3.11. 
<img src="https://www.benzinga.com/files/images/story/2024/1734548409_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of 8x8 among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$2.60</td>
<td>$2.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$2.50</td>
<td>$2.75</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$2.00</td>
<td>$1.50</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2.75</td>
<td>$2.50</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$2.50</td>
<td>$2.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Josh Nichols</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$4.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 8x8. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of 8x8 compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of 8x8's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of 8x8's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EGHT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on 8x8 analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About 8x8</h2>
8x8 Inc provides contact-center-as-a-service and unified-communications-as-a-service software applications to approximately 2.5 million users. The company's unified platform enables omnichannel communication to assist employees in communicating across voice, video, text, chat, and contact centers. The Company also generates revenue from sales of hardware and professional services, which are complementary to the delivery of its integrated technology platform.. Geographically, it derives a majority of revenue from the United States.
<h3>Financial Insights: 8x8</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Negative Revenue Trend: Examining 8x8's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -2.16% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: 8x8's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -8.03%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -13.57%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): 8x8's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.94%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 4.2, 8x8 faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EGHT

A Glimpse Into The Expert Outlook On 8x8 Through 7 Analysts

In the current market session, Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) stock price is at $671.67, after a 0.90% drop. However, over the past month, the company's stock increased by 3.24%, and in the past year, by 8.16%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1734548408_0.png" alt="Past Year Chart" />

<h3>How Does Intuit P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 95.11 in the Software industry, Intuit Inc. has a lower P/E ratio of 65.93. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734548408_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

INTU

A Look Into Intuit Inc's Price Over Earnings

Fed Cuts Key Overnight Rate By 25 bps

Wall Street analysts rerated Salesforce, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) after it announced that a second generation&nbsp;of its Agentforce technology, capable of tackling questions in Salesforce&#8217;s Slack communications app, will be&nbsp;available in February 2025. The company also announced plans to <a target="_blank" href="https://www.benzinga.com/media/24/12/42550951/salesforce-doubles-ai-hiring-goal-to-add-2k-sales-roles" rel="noreferrer noopener">hire 2,000 artificial intelligence-focused salespeople.</a>
Needham analyst Scott Berg maintained Salesforce with a Buy and a $375 price target. BofA Securities analyst Brad Sills reiterated a Buy on Salesforce with a price target of $440.
Goldman Sachs analyst Kash Rangan maintained a Buy rating on Salesforce with a <a target="_blank" href="https://www.benzinga.com/quote/CRM/analyst-ratings" rel="noreferrer noopener">price target of $400.</a>
Truist analyst Terry Tillman reiterated a Buy rating on Salesforce with a price target of $400. Wedbush analyst Daniel Ives maintained Salesforce with an Outperform and a $425 price target.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42535990/mccormick-eyes-1-billion-deal-to-acquire-dukes-mayonnaise-maker" rel="noreferrer noopener">McCormick Eyes $1 Billion Deal To Acquire Duke&#8217;s Mayonnaise Maker</a>
Needham: Berg virtually attended Salesforce&#8217;s Agentforce 2.0 release, coming away optimistic regarding updated Agentforce deal metrics (1000+ deals closed versus 200+ as of third-quarter) along with the expanded capabilities of the new platform.
Compared to version 1.0, which focuses on Sales and Service-oriented support, 2.0 looks to help internal processes and enterprise information gathering by leveraging Slack as the central Agent &#8220;hub&#8221; to pull information together across enterprise platforms.
Agentforce 2.0 highlights the Halo effect with Mulesoft and Data Cloud even more than Gen 1. Enhancements to the Atlas Reasoning Engine will further expand usage into more complex use cases. With an estimated TAM expansion of over $740 billion through AI spending, Agentforce seems poised to drive incremental top-line growth, which Berg noted as more tilted toward fiscal 2027. Berg projected fourth-quarter revenue of $10.04 billion and adjusted EPS of $2.60.
BofA Securities: Sills attended Salesforce&#8217;s Agentforce 2.0 launch virtually on Tuesday. The analyst is encouraged by the platform&#8217;s progress, which is now embedded into sales, marketing, Slack, and others. Also, the company is expanding the scope of Agentforce to integrate data for workflow across key third-party applications.
Finally, Agentforce 2.0 bolsters the AI platform with enhanced reasoning via the Atlas engine. Sills remains bullish on the agent opportunity for Salesforce in fiscal 2026 and the longer term. The analyst estimates Agentforce could provide incremental 1%-2% points of revenue growth in fiscal 2026 and 2027 each. The stock remains his top pick.
Goldman Sachs: Rangan rerated on the back of Salesforce&#8217;s Agentforce 2.0 event, which continues to amplify the company&#8217;s technical leadership. The analyst returned incrementally positive on Salesforce&#8217;s execution of its Gen-AI product roadmap with the development of enhanced capabilities within months of Agentforce&#8217;s release in September and delivery of quick-to-value productivity benefits.
With Agentforce 2.0 seamlessly connecting workflows with a knowledge graph across the entire product suite, Rangan noted Salesforce further solidifying its value proposition beyond a traditional tool. With over 1,000 Agentforce deals closed and thousands more in the pipeline, Rangan highlighted early proof points supporting Salesforce&#8217;s product-market fit and long-term growth durability. These deals indicate that Salesforce is well-positioned to capture a share in the growing digital labor market as the proliferation of Gen-AI augments human capacity.
While this might take time to drive meaningful revenue contribution, Rangan noted near-term tailwinds stemming from macro improvement, IT budget unlock as AI spending moves into the application layer, Data Cloud&#8217;s added contribution as it approaches ~$1 billion, and cyclical improvements in Marketing and Commerce Cloud.
Truist: Tillman virtually attended Salesforce&#8217;s Agentforce 2.0 unveiling event. Along with several product roadmap updates, the company has disclosed closing 1,000 paid Agentforce deals. Recall that Salesforce signed 200 Agentforce deals in the third quarter of 2025, which Tillman noted was approximately quadruple the company&#8217;s initial expectations.
Other highlights included notable internal efficiency stats with Agentforce, currently available Agent skills updates, and a fulsome roadmap, including several critical upcoming updates to Salesforce&#8217;s Atlas Reasoning Engine. Tillman noted that the company maintains an improved pace of innovation with Agentforce capabilities and anticipates major releases through the calendar of 2025, including Agentforce 3.0 in May.
Tillman noted that the premium on revenue versus peers is well justified given that the company offers an attractive balance of growth at scale and expanding profitability and cash flow, all with multiple capital allocation avenues setting the stage for consistent long-term shareholder returns. Also, the potential for growth acceleration while continuing to expand margins bodes well for potential upside and higher valuation implications
Wedbush: The company&#8217;s agents are built to handle routine use cases so humans can focus on handling difficult situations with significantly higher resolution on sales and services issues, with ~5k conversations being passed to humans out of ~32k conversations per week.
With the AI Revolution entering the software phase heading into 2025, Salesforce is well positioned to capture its fair share of market expansion as the AI monetization phase will catalyze Salesforce&#8217;s development over the next 12 to 18 months with a $7 trillion digital labor market opportunity on the horizon for Salesforce. 
Ives noted Salesforce is a clear second derivative beneficiary of the AI Revolution that could add ~$80 per share to the Salesforce story as this monetization story takes shape over the next 12 to 18 months with CEO Marc Benioff leading the charge and this new era of AI growth. Ives projected fourth-quarter revenue of $10.01 billion and adjusted EPS of $2.60.
Price Action: CRM stock traded higher by 0.23% to $351.77 at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42530171/walmart-teams-up-with-chinas-meituan-to-boost-e-commerce" target="_blank" rel="noreferrer noopener">Walmart Teams Up With China&#8217;s Meituan to Boost E-Commerce</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

Price Target

Reiteration

Tech

Wall Street Analysts Are Bullish On Salesforce's AI Vision - Here's Why

GRRR

Gorilla Technology shares are trading higher after the company announced it completed the conversion and elimination of its preferred shares for an enhanced capital structure.

JPMorgan analyst Cory Carpenter downgraded Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) stock from <a href="https://www.benzinga.com/quote/GETY/analyst-ratings" target="_blank" rel="noreferrer noopener">Neutral to Underweight</a>. The stock price declined after the rerating.
Getty Images is a leading visual content creator and marketplace that connects over 576,000 content creators with 719,000 purchasing customers.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/24/12/42536593/verizon-teams-up-with-nvidia-to-power-ai-apps-over-private-5g-networks" rel="noreferrer noopener">Verizon Teams Up With Nvidia To Power AI Apps Over Private 5G Networks</a>
The rerating reflects Getty Images stock trading at a healthy premium to Shutterstock Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSTK#NYSE">SSTK</a>), uncertainty around the potential longer-term impact from generative AI on the industry, potential growth headwinds in 2025 (lapping even-year events + FX) and limited capital allocation flexibility.
Getty Images returned to growth in recent quarters driven by a strong event calendar (U.S. election and Olympics), lapping easier Hollywood strike comps and agency channel stability.
Carpenter expects these trends to persist in the fourth quarter but noted the 2025 setup will be more challenging as the event calendar turns into a ~$10 million-$12 million headwind and Getty Images has high foreign exchange exposure relative to the rest of the analyst&#8217;s coverage universe.
Carpenter expects this to translate into limited revenue growth and margin expansion in 2025. This, coupled with ongoing uncertainty around the potential longer-term impact of generative AI on the industry, Getty Images trading at a healthy premium to Shutterstock, warrant litigation overhang and limited capital allocation flexibility, gives the analyst a cautious bias on the stock next year.
GETY Price Action: Getty Images stock is down 4.67% at $2.45 at publication Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42536024/taiwan-eyes-amazons-kuiper-as-starlink-faces-hurdles" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Project Kuiper In Talks With Taiwan For Satellite Partnership</a></li>
</ul>
Photo: Shutterstock

Downgrades

Movers

Media

GETY

SSTK

Getty Images' AI Uncertainty, FX Headwinds, Premium Valuation Spark Downgrade

NOTV, BFRI and CPOP among pre-market losers

SPWR, BIG and BOLT among pre-market losers

NewGenIvf receives Nasdaq non-compliance notifications

NewGenIvf updates on potential reverse merger with COVIRIX

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news to start the day with!



Moving stocks this morning a partnerships, a public offering, clinical trial news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rocketing more than 123% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring over 75% with strong early morning trading.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is surging more than 45% <a href="https://www.nasdaq.com/press-release/hoth-therapeutics-partners-lts-therapy-systems-accelerate-novel-alzheimers-treatment">on a new partnership</a> to develop its Alzheimer&rsquo;s treatment.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are increasing over 44% after encouraging investors to <a href="https://finance.yahoo.com/news/allarity-encourages-shareholders-vote-reverse-100000785.html">vote for a reverse stock split</a>.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is heading more than 33% higher alongside strong pre-market trading.</li>



<li>Pieris Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pirs-stock-quote/">PIRS</a>) shares are rising over 28% after <a href="https://www.nasdaq.com/press-release/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement">announcing a merger agreement</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is jumping more than 23% with heavy early morning trading today.</li>



<li>NewGenIvf (NASDAQ:<a href="https://investorplace.com/stock-quotes/nivf-stock-quote/">NIVF</a>) shares are climbing over 22% after providing a <a href="https://www.nasdaq.com/press-release/newgenivf-provides-update-potential-reverse-merger-covirix-2024-07-23">reverse merger update</a>.</li>



<li>Perfect Moment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/">PMNT</a>) stock is getting a close to 19% boost after announcing a <a href="https://www.nasdaq.com/press-release/perfect-moment-teams-quiet-platforms-establish-distribution-center-us-2024-07-22">distribution center agreement</a>.</li>



<li>Catheter Precision (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vtak-stock-quote/">VTAK</a>) shares are up more than 16% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is crashing over 73% but only <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">after a massive rally yesterday</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are plummeting 28% on <a href="https://www.12newsnow.com/article/news/local/texas/conns-reportedly-planning-mass-closures/502-4db60564-6fdd-4ffa-ae26-899bec91f75c">reports of impending store closures</a>.</li>



<li>ATI Physical Therapy (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/">ATIP</a>) stock is diving more than 25% without any obvious news this morning.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are tumbling over 25% on a <a href="https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200500583.html">proposed public offering</a>.</li>



<li>Agape ATP (NASDAQ:<a href="https://investorplace.com/stock-quotes/atpc-stock-quote/">ATPC</a>) stock is taking an almost 24% beating after a rally yesterday.</li>



<li>AtlasClear (NYSEMKT:<a href="https://investorplace.com/stock-quotes/atch-stock-quote/">ATCH</a>) shares are sliding more than 22% despite a lack of news on Wednesday.</li>



<li>Sage Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/sage-stock-quote/">SAGE</a>) stock is dropping over 22% after reporting <a href="https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-topline-results-phase-2-kinetic-2-study-sage">Phase 2 topline results</a>.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) shares are decreasing more than 21% <a href="https://www.nasdaq.com/press-release/volato-updates-fractional-program-additional-differentiated-benefits-2024-07-23">after a recent rally</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) stock is slipping over 19% following yesterday&rsquo;s rally.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares close out our pre-market stock movers down more than 19% after a rally yesterday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

NewGenIvf surges after binding term sheet news with White Lion for $100M equity line of credit

NewGenIvf Group (NIVF) has entered into a binding term sheet with White Lion Capital, setting out the principal terms and conditions for a $100 mil...

NewGenIvf Group enters binding term sheet with White Lion Capital

NewGenIvf gets delisting notice from Nasdaq

NewGenIvf Group (NIVF) announced that on November 21 2024, it received written notice from The Nasdaq Stock Market that its securities are subject ...

NewGenIvf Group receives Nasdaq delisting notice, plans to appeal

NewGenIvf Group (NIVF) has entered into a binding term sheet regarding the previously announced proposed reverse merger with healthcare company Eur...

NewGenIvf Group announces proposed reverse merger with EWIHL

ACIU

ALLR

ATCH

ATIP

ATPC

AZTR

BBLG

BFRI

BOLT

CJET

CONN

CPOP

CTNT

DRMA

HOLO

HOTH

KOSS

NOTV

NUZE

OKLO

PIRS

PMNT

RYDE

SAGE

SLRX

SOAR

SPWR

VRPX

VSTM

VTAK

Health Care

The Search Is Over: NewGenIVF Inks Reverse Merger Agreement With European Wellness Investment Holdings

Press Releases

NewGenIvf Provides Update on Potential Reverse Merger with COVIRIX

NewGenIvf Announces Filing of 2023 Annual Report with the SEC

NewGenIvf Receives Nasdaq Notification Regarding Minimum Bid Price

Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF

Peraso Inc. (NASDAQ: PRSO): Revolutionizing Military Combat with Steerable Beam Technology see more stocks inside…

Financing

NewGenIvf Enters into a Binding Term Sheet with White Lion Capital for $100 Million Equity Line of Credit, Expandable to $500 Million

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

NewGenIvf Receives Nasdaq Delisting Notice and Plans to Submit Appeal, Announces Strategic Path Forward to Regain Compliance

Contracts

NewGen Signs Binding Term Sheet for Reverse Merger with European Wellness Investment Holdings

AGBA

APLM

BNZI

BREA

CRDL

DRUG

HCWB

ILLR

NIXX

PRSO

RANI

SINT

STAF

TVGN

VMAR

VSME

XPON

American Shared Hospital Services Common Stock

American Shared Hospital

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Kindly MD

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

Ontrak

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

SHL Telemedicine

Syra Health

Vivos Therapeutics

Comments

NewGenIvf Group

NewGenIvf Group (NIVF) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL